Paola Gargiulo, Christian Basile, Gennaro Galasso, Michele Bellino, Debora D'Elia, Giuseppe Patti, Manuel Bosco, Matteo Prinetti, Giuseppe Andò, Francesca Campanella, Giovanni Taverna, Paolo Calabrò, Arturo Cesaro, Fabio Fimiani, Angelo Catalano, Ferdinando Varbella, Antonella Corleto, Francesco Barillà, Saverio Muscoli, Giuseppe Musumeci, Fabrizio Delnevo, Francesco Giallauria, Raffaele Napoli, Italo Porto, Alberto Polimeni, Rossella Quarta, Alessandro Maloberti, Piera Angelica Merlini, Leonardo De Luca, Gavino Casu, Natale Daniele Brunetti, Mario Crisci, Leonardo Paloscia, Claudio Bilato, Ciro Indolfi, Federica Marzano, Sara Fontanarosa, Davide Buonocore, Antonio Luca Maria Parlati, Ermanno Nardi, Maria Prastaro, Andrea Soricelli, Marco Salvatore, Stefania Paolillo, Pasquale Perrone-Filardi
AIMS: No data are available on early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in patients with acute coronary syndrome (ACS) in real-world. This study investigates the effects of PCSK9i started at time of ACS hospitalization on lipid control and major CV events in real-world. METHODS: The lipid control outcome was the percentage of patients reaching the LDL-C target of < 55 mg/dL at first lipid control. The clinical outcome was the incidence of composite major CV events (all cause death, non-fatal MI, non-fatal stroke, and ischemia-driven revascularization) during follow-up in relation to quartiles of LDL-C at first lipid control...
May 24, 2024: European Journal of Preventive Cardiology